HEXVIX VERUS WHITE LIGHT GUIDED TURB FOR EORTC SCORE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWED BY ATTENUATED INTRAVESICAL ADJUVANT CHEMOTHERAPY.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Feb 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hexyl aminolevulinate (Primary) ; Mitomycin; Mitomycin
Indications Bladder cancer
Focus Diagnostic use
Acronyms HELENA

Most Recent Events

05 Feb 2021 This trial has been completed in Germany, according to European Clinical Trials Database record. (Global end date:2020-10-30)
10 Nov 2012 Planned end date changed from 8 Sep 2011 to 8 Jan 2015 as reported by European Clinical Trials Database.
15 Jun 2011 New trial record

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight